Immuneering CEO to Outline Pipeline Strategy at Leerink Conference
Event summary
- Immuneering CEO Ben Zeskind to present at Leerink Global Healthcare Conference on March 9, 2026.
- Fireside chat scheduled for 3:40–4:10 pm ET, followed by 1x1 investor meetings.
- Presentation to cover pipeline, platform, and business strategy.
- Lead candidate atebimetinib set for Phase 3 trial in pancreatic cancer mid-2026.
- Company developing Deep Cyclic Inhibitors targeting tumor shrinkage, cachexia, and side effects.
The big picture
Immuneering’s presentation comes as late-stage oncology companies face increasing pressure to demonstrate differentiated survival benefits. The focus on Deep Cyclic Inhibitors reflects a broader industry shift toward therapies that address both tumor reduction and patient quality of life. Success in pancreatic cancer could position Immuneering as a key player in MAPK pathway-driven treatments.
What we're watching
- Clinical Execution
- Whether Immuneering can successfully initiate and complete the Phase 3 MAPKeeper 301 trial for atebimetinib in pancreatic cancer.
- Pipeline Expansion
- The pace at which Immuneering advances additional combination therapies and early-stage programs.
- Investor Sentiment
- How investor perception of Immuneering’s strategy evolves post-conference presentation.
Related topics